Oncolytics downgraded to Hold from Buy at JonesResearch

JonesResearch analyst Soumit Roy downgraded Oncolytics (ONCY) to Hold from Buy without a price target The company is continuing to actively search for a Chief Executive Officer, as well as exploring potential business development opportunities, the analyst tells investors in a research note. The firm says it needs to get a better understanding on Oncolytics’ path forward “as there is an immediate need for capital.”